Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study

Haematologica. 2016 Apr;101(4):e139-41. doi: 10.3324/haematol.2015.138388. Epub 2015 Dec 24.
No abstract available

Keywords: ABVD; Hodgkin lymphoma; brentuximab vedotin; early; intermediate; radiotherapy; toxicity.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Brentuximab Vedotin
  • Drug Administration Schedule
  • Female
  • Fever / diagnosis
  • Fever / etiology
  • Fever / pathology
  • Gamma Rays / therapeutic use*
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / pathology
  • Hodgkin Disease / radiotherapy*
  • Humans
  • Immunoconjugates / administration & dosage*
  • Immunoconjugates / adverse effects
  • Male
  • Middle Aged
  • Nausea / diagnosis
  • Nausea / etiology
  • Nausea / pathology
  • Neoplasm Staging
  • Neutropenia / diagnosis
  • Neutropenia / etiology
  • Neutropenia / pathology
  • Pilot Projects
  • Remission Induction
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Immunoconjugates
  • Brentuximab Vedotin